Synopsis
Synopsis
0
JDMF
0
KDMF
0
VMF
0
FDA Orange Book
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Magnesium Citrate Dibasic, Anhydrous
2. 144-23-0
3. 7779-25-1
4. Magnesiumcitrate(x:1)
5. Magnesium Citrate(x:1)
6. Akos028109527
7. J-007935
Molecular Weight | 214.41 g/mol |
---|---|
Molecular Formula | C6H6MgO7 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 3 |
Exact Mass | 213.9963942 g/mol |
Monoisotopic Mass | 213.9963942 g/mol |
Topological Polar Surface Area | 138 Ų |
Heavy Atom Count | 14 |
Formal Charge | 0 |
Complexity | 234 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 35749
Submission : 2021-03-29
Status : Active
Type : IV
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 35750
Submission : 2021-03-29
Status : Active
Type : IV
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 27073
Submission : 2013-04-08
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 15548
Submission : 2001-07-26
Status : Inactive
Type : II
Date of Issue : 2022-02-03
Valid Till : 2025-02-03
Written Confirmation Number : WC-0518
Address of the Firm :
Certificate Number : R0-CEP 2009-151 - Rev 00
Issue Date : 2010-10-26
Type : Chemical
Substance Number : 2339
Status : Withdrawn by EDQM F...
Date of Issue : 2022-06-08
Valid Till : 2025-07-07
Written Confirmation Number : WC-0104
Address of the Firm :
Certificate Number : R1-CEP 2009-017 - Rev 03
Issue Date : 2021-10-29
Type : Chemical
Substance Number : 2339
Status : Valid
Certificate Number : R1-CEP 2015-129 - Rev 01
Issue Date : 2022-10-19
Type : Chemical
Substance Number : 2339
Status : Valid
Certificate Number : CEP 2011-036 - Rev 03
Issue Date : 2025-01-03
Type : Chemical
Substance Number : 2402
Status : Valid
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
11
PharmaCompass offers a list of Magnesium Citrate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Magnesium Citrate manufacturer or Magnesium Citrate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Magnesium Citrate manufacturer or Magnesium Citrate supplier.
PharmaCompass also assists you with knowing the Magnesium Citrate API Price utilized in the formulation of products. Magnesium Citrate API Price is not always fixed or binding as the Magnesium Citrate Price is obtained through a variety of data sources. The Magnesium Citrate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Trimagnesium Dicitrate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Trimagnesium Dicitrate, including repackagers and relabelers. The FDA regulates Trimagnesium Dicitrate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Trimagnesium Dicitrate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Trimagnesium Dicitrate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Trimagnesium Dicitrate supplier is an individual or a company that provides Trimagnesium Dicitrate active pharmaceutical ingredient (API) or Trimagnesium Dicitrate finished formulations upon request. The Trimagnesium Dicitrate suppliers may include Trimagnesium Dicitrate API manufacturers, exporters, distributors and traders.
click here to find a list of Trimagnesium Dicitrate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Trimagnesium Dicitrate DMF (Drug Master File) is a document detailing the whole manufacturing process of Trimagnesium Dicitrate active pharmaceutical ingredient (API) in detail. Different forms of Trimagnesium Dicitrate DMFs exist exist since differing nations have different regulations, such as Trimagnesium Dicitrate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Trimagnesium Dicitrate DMF submitted to regulatory agencies in the US is known as a USDMF. Trimagnesium Dicitrate USDMF includes data on Trimagnesium Dicitrate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Trimagnesium Dicitrate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Trimagnesium Dicitrate suppliers with USDMF on PharmaCompass.
A Trimagnesium Dicitrate CEP of the European Pharmacopoeia monograph is often referred to as a Trimagnesium Dicitrate Certificate of Suitability (COS). The purpose of a Trimagnesium Dicitrate CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Trimagnesium Dicitrate EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Trimagnesium Dicitrate to their clients by showing that a Trimagnesium Dicitrate CEP has been issued for it. The manufacturer submits a Trimagnesium Dicitrate CEP (COS) as part of the market authorization procedure, and it takes on the role of a Trimagnesium Dicitrate CEP holder for the record. Additionally, the data presented in the Trimagnesium Dicitrate CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Trimagnesium Dicitrate DMF.
A Trimagnesium Dicitrate CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Trimagnesium Dicitrate CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Trimagnesium Dicitrate suppliers with CEP (COS) on PharmaCompass.
A Trimagnesium Dicitrate written confirmation (Trimagnesium Dicitrate WC) is an official document issued by a regulatory agency to a Trimagnesium Dicitrate manufacturer, verifying that the manufacturing facility of a Trimagnesium Dicitrate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Trimagnesium Dicitrate APIs or Trimagnesium Dicitrate finished pharmaceutical products to another nation, regulatory agencies frequently require a Trimagnesium Dicitrate WC (written confirmation) as part of the regulatory process.
click here to find a list of Trimagnesium Dicitrate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Trimagnesium Dicitrate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Trimagnesium Dicitrate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Trimagnesium Dicitrate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Trimagnesium Dicitrate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Trimagnesium Dicitrate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Trimagnesium Dicitrate suppliers with NDC on PharmaCompass.
Trimagnesium Dicitrate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Trimagnesium Dicitrate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Trimagnesium Dicitrate GMP manufacturer or Trimagnesium Dicitrate GMP API supplier for your needs.
A Trimagnesium Dicitrate CoA (Certificate of Analysis) is a formal document that attests to Trimagnesium Dicitrate's compliance with Trimagnesium Dicitrate specifications and serves as a tool for batch-level quality control.
Trimagnesium Dicitrate CoA mostly includes findings from lab analyses of a specific batch. For each Trimagnesium Dicitrate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Trimagnesium Dicitrate may be tested according to a variety of international standards, such as European Pharmacopoeia (Trimagnesium Dicitrate EP), Trimagnesium Dicitrate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Trimagnesium Dicitrate USP).